Borealis Biosciences is a company in the field of next-generation RNA medicines.
Borealis Biosciences has raised $30.0M in total funding. The most recent round was Series A. The last funding was announced in December 2024.
Borealis Biosciences's investors include Novartis, Versant Ventures, Westlake Village BioPartners.
Borealis Biosciences is headquartered in Vancouver, Canada.
Borealis Biosciences is a company in the field of next-generation RNA medicines.
Borealis Biosciences is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Borealis Biosciences — Funding & Investors." VCBacked, December 19, 2024, https://www.vcbacked.co/company/borealis-biosciences. Accessed October 16, 2026.
VCBacked. (2024). Borealis Biosciences — Funding & Investors. Retrieved October 16, 2026, from https://www.vcbacked.co/company/borealis-biosciences
{{cite web |title=Borealis Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/borealis-biosciences |website=VCBacked |access-date=October 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated